Edition:
United States

Bio Rad Laboratories Inc (BIO.N)

BIO.N on New York Stock Exchange

230.89USD
21 Sep 2017
Change (% chg)

$-2.26 (-0.97%)
Prev Close
$233.15
Open
$232.64
Day's High
$232.64
Day's Low
$230.00
Volume
31,998
Avg. Vol
34,710
52-wk High
$242.58
52-wk Low
$154.89

Chart for

About

Bio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a... (more)

Overall

Beta: 0.92
Market Cap(Mil.): $6,815.08
Shares Outstanding(Mil.): 29.58
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.63 16.33
EPS (TTM): -- -- --
ROI: -- 13.80 14.66
ROE: -- 16.62 13.99

BRIEF-U.S. ITC to probe certain 10X Genomics devices after Bio-Rad complaint

* U.S. U.S. International Trade Commission says it will investigate certain microfluidic devices by 10x Genomics Inc after complaint by Bio-rad Laboratories Inc and Lawrence Livermore National Security LLC. Source text for Eikon: Further company coverage: (Reporting By Susan Heavey)

Aug 31 2017

BRIEF-Bio-Rad reports Q2 earnings per share $0.17

* Q2 earnings per share view $0.56 -- Thomson Reuters I/B/E/S

Aug 03 2017

Bio-Rad brings patent case against upstart rival 10X Genomics

The life sciences company Bio-Rad Laboratories Inc on Monday accused its upstart rival 10X Genomics of selling DNA analysis machines that infringe its patents.

Aug 01 2017

BRIEF-Virbac signs a research agreement with Bio-Gene

* VIRBAC SA - VIRBAC SIGNS A RESEARCH AGREEMENT WITH BIO-GENE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 16 2017

BRIEF-Bio Rad Laboratories receives FDA clearance for Bioplex 2200 syphilis total & RPR assay​

* Bio Rad Laboratories Inc - ‍has received U.S. Food and Drug Administration clearance for its Bioplex 2200 syphilis total & RPR assay​ Source text for Eikon: Further company coverage:

Jun 12 2017

BRIEF-Bio-Rad introduces enhanced options with its IH-COM data management software

* Bio-Rad introduces enhanced options with its IH-COM data management software for managing patient results with the IH-1000 system Source text for Eikon: Further company coverage:

May 24 2017

BRIEF-Amicogen buys 9.1 pct stake in Bio-Works Technologies AB

* Says it has acquired 895,000 shares in Bio-Works Technologies AB, and is holding 9.1 percent stake in the co, from 0 percent stake

May 18 2017

BRIEF-Autobio Diagnostics to invest in 75 pct stake in bio-tech firm Bio-top

* Says it plans to invest up to 202.5 million yuan ($29.32 million) for 75 percent stake in Beijing-based bio-tech firm Bio-top

May 09 2017

BRIEF-Bio-Rad Laboratories reports Q1 earnings per share $0.41

* Q1 revenue $500.1 million versus I/B/E/S view $477.8 million

May 04 2017

Fitch Affirms Bio-Rad's IDR at 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) AUSTIN, April 05 (Fitch) Fitch Ratings has affirmed the ratings of Bio-Rad Laboratories, Inc. (Bio-Rad), including the 'BBB-' Issuer Default Rating (IDR). The ratings apply to approximately $437 million of debt at Dec. 31, 2016. The Rating Outlook is Stable. A full list of rating actions follows at the end of this release. KEY RATING DRIVERS Evolving Capital Allocation Strategy: Bio-Rad recently announced long-term targets for revenue g

Apr 05 2017

Earnings vs. Estimates